Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
Toronto, Ontario--(Newsfile Corp. - August 18, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed its first licensing partnership agreement in Canada with Wellbeings® Pain Management and Dependency Clinic (Wellbeings). The agreement will enable Ontario based...
2022-08-18 7:45 AM EDT
Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist
Toronto, Ontario--(Newsfile Corp. - August 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed a licensing partnership agreement with Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) ("Revitalist"), one of the largest publicly...
2022-08-15 9:00 AM EDT
Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs
Toronto, Ontario--(Newsfile Corp. - July 20, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today that the National Institute for Health and Care Research (NIHR), a UK government agency, has approved grant funding for 66% of the costs of Awakn's Phase III clinical trial...
2022-07-20 7:30 AM EDT
Awakn Life Sciences Provides a Business and Corporate Update
Toronto, Ontario--(Newsfile Corp. - July 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) is today providing a business and corporate update. Awakn launches 'Beta' phase of its Licensing and Partnerships business in North America. Awakn has signed Memorandum of Understanding (MOU)...
2022-07-15 7:30 AM EDT
Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program - Ketamine-Assisted Therapy for Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - July 5, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a revenue-generating biotechnology company researching, developing and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce it has secured funding from Innovate UK to identify the quickest and most cost-effective route to market in both the UK and the US for Awakn's lead program - proprietary...
2022-07-05 7:30 AM EDT
Awakn Life Sciences to Present in Upcoming June 2022 Conferences
Toronto, Ontario--(Newsfile Corp. - June 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) is pleased to announce that the company's CEO Anthony Tennyson will be presenting at two investor conferences this June.Emerging Growth Conference 33Date: Wednesday June 22nd, 2022Location:...
2022-06-17 9:03 AM EDT
Awakn Life Sciences Reports Results for Quarter Ended April 30, 2022
Toronto, Ontario--(Newsfile Corp. - June 14, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today its financial results and business highlights for the three months ended April 30, 2022. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars...
2022-06-14 5:00 PM EDT
Awakn Life Sciences Appoints Biotech and Investment Veteran Dennis Purcell as a Special Advisor to the CEO
Toronto, Ontario--(Newsfile Corp. - June 7, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today that Dennis Purcell has joined Awakn as a Special Advisor to the CEO.Mr. Purcell brings a wealth of life science and investment experience to Awakn. Mr. Purcell is the Founder of Aisling Capital...
2022-06-07 7:30 AM EDT
Awakn Life Sciences Initiates Follow-On Behavioral Study to Focus on Gambling Disorder
Toronto, Ontario--(Newsfile Corp. - June 2, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today that they have initiated a larger behavioral addiction study investigating ketamine as a treatment for Gambling Disorder. Awakn announced on May 19, 2022, that the Company had completed a successful...
2022-06-02 7:30 AM EDT
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application for the Treatment of Behavioral Addictions
Toronto, Ontario--(Newsfile Corp. - May 26, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction, announced today the filing of a Patent Cooperation Treaty (PCT) application for the treatment of behavioral addictions with ketamine and ketamine-assisted psychotherapy. The successful completion of Awakn's behavioral addictions study was announced last week and the...
2022-05-26 7:30 AM EDT
Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for 'The Investor Hotseat' via Live Stream on May 26th
Toronto, Ontario--(Newsfile Corp. - May 24, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that the company's CEO, Anthony Tennyson, will be attending The Investor Hotseat live stream event conducted by Psychedelic Invest. He will be joined in conversation with the host Dustin...
2022-05-24 7:30 AM EDT
Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions
Toronto, Ontario--(Newsfile Corp. - May 19, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today the completion of the world's first ketamine treatment study for behavioral addictions. The behavioral addictions included in the study were Gambling Disorder, Internet Gaming Disorder, Binge Eating...
2022-05-19 7:55 AM EDT
Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer
Toronto, Ontario--(Newsfile Corp. - May 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today that Dr. Arun Dhandayudham is joining Awakn as its Chief Medical Officer. Dr. Ben Sessa is stepping back from his role as CMO to become Awakn's Head of Psychedelic Medicine, allowing him to continue...
2022-05-17 7:30 AM EDT
Awakn Life Sciences to Participate in Upcoming May 2022 Conferences
Toronto, Ontario--(Newsfile Corp. - May 5, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction, announced today that Awakn's management team is scheduled to present at the following upcoming May 2022 conferences. PSYCH Symposium: London 2022Date: Wednesday, May 11, 2022Location: The National Gallery in London, UKPresentations: Professor David Nutt, Chief...
2022-05-05 7:30 AM EDT
Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results
Toronto, Ontario--(Newsfile Corp. - April 28, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction, today is reporting its financial results and business highlights for the three and twelve months ended January 31, 2022. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise...
2022-04-28 4:30 PM EDT
Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway
Toronto, Ontario--(Newsfile Corp. - April 13, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering revolutionary therapeutics to treat addiction, today is providing shareholders with a business update on its three fully-operational ketamine-assisted therapy clinics, two in the UK and one in Norway. Awakn's clinics team consists of some of the world's leading authorities in the...
2022-04-13 7:30 AM EDT
Awakn Successfully Completes Phase One of Its Drug Discovery Program
Toronto, Ontario--(Newsfile Corp. - April 6, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering revolutionary therapeutics to treat addiction, announced today the successful completion of phase one of its new chemical entity (NCE) development program, strengthening Awakn's pipeline for the treatment of a broad range of both substance and behavioural addictions. Awakn has completed a hit to lead...
2022-04-06 7:30 AM EDT
Awakn Life Sciences to Participate in Upcoming April 2022 Conferences
Toronto, Canada--(Newsfile Corp. - April 5, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, announced today that Anthony Tennyson, Awakn's Chief Executive Officer, is scheduled to present at the following upcoming April 2022 investor conferences. Sequire Cannabis & Psychedelic ConferenceWednesday, April 20th at 3:00 p.m. ETTo attend, please register...
2022-04-05 7:30 AM EDT
Awakn Life Sciences Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - March 22, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, is pleased to announce that they have closed a non-brokered private placement through the issuance of 2,031,250 units (the "Units") at a price of $1.60 per Unit for gross proceeds of $3,250,000 (the "Offering"). Each Unit is comprised of one...
2022-03-22 7:30 AM EDT
Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
Mental HealthThird Location Adds to Two Existing Operatons in Bristol and Oslo Toronto, Ontario--(Newsfile Corp. - March 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that Awakn Clinics London has received Care Quality Commission's (CQC) formal approval to begin treatments for addiction and mental health.The flagship London...
2022-03-17 7:30 AM EDT